You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201491 - 201500 of 207728 results
  1. IGF::OT::IGF Laser-driven Proton and Carbon Therapy

    SBC: RADIABEAM TECHNOLOGIES, LLC            Topic: NCI

    Not Available

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. IGF::OT::IGF Title: SMART Fusion: High Affinity Peptide Capture Reagents PoP: 0

    SBC: A&G PHARMACEUTICAL, INC.            Topic: NCI

    The purpose of this application is to develop realiable, renewable, cost effective, specific, high affinity antipeptide affitnity reagent to be successfully used in mass spec based cancer biomarker detection methods such as SISCAPA, for the analysis of patient plasma. Early detection of cancer is a key to successful and cost effective treatment. Routine monitoring of the plasma biomaker levels is ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. TOPIC 319 TECHNOLOGY TO GENERATE ANTI PEPTIDE CAPTUE REAGENTS FOR AFFINITY ENRIFH

    SBC: Operational Techologies Corporation            Topic: NCI

    Operational Technologies Corp. (OpTech) proposes to develop DNA aptamers against ten or more phosphorylated peptides from NCI's list of proteomic targets. These aptamers will be biotinylated and coupled to streptavidin-coated magnetic microbeads (MBs) or covalently bound to MBs, if necessary. The aptamer-MB reagents will be used to bind and enrich for their specific peptides in chaotrope and ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. PDX Pharmaceuticals

    SBC: PDX PHARMACEUTICALS, INC.            Topic: NCI

    Over one million women worldwide are diagnosed with breast cancer each year. Roughly 20% of all breast cancers overexpress the human epidennal growth receptor 2 (HER2-positive subtype). HER2-targeted therapies, including Herceptin and lapatinib, account for 55% of the breast cancer therapy market in 2011 (or 5 billion annually). Response to HER2-targeted therapies typically average about one year ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. For Life: An Online Relapse Prevention Tool for Adolescent Substance Abusers

    SBC: 3-C Institute for Social Development, Inc.            Topic: NIDA

    Prototype Development and Refinement. We will develop a prototype with 2 games targeting coping skills for relaxation and substance refusal. The prototype will provide interactive instructional segments for each game along with game play to learn about andpractice each of these skill areas within an engaging virtual environment. We also will develop a prototype of the For Life Parent Guide focused ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Relapse Prevention Motion Video Game

    SBC: MEDIA REZ LLC            Topic: NIDA

    Aim 1: Concept Testing: To elicit qualitative feedback from adolescents age in recovery, ages 15-18, in a focus group format (n=9) on the concept of Recovery Warrior and the proposed design features of Recovery Warrior. PUBLIC HEALTH RELEVANCE

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Contract HHSN271201300008C, SBIR-I, Topic 001, A Scalable Multi-Scale Visual An

    SBC: Intelligent Automation, Inc.            Topic: NIDA

    The primary objective of this Phase I effort is to demonstrate the feasibility of the proposed SMS-VAT tool to support clinicians and medical researchers to handle the ever-growing translational science data. Specific objectives include: Objective 1:Demonstrate the preparation of good datasets for visualization using information extraction, network construction and mining. The success of this ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. FY 2013 SBIR-I Contract for Automated Instrument to Clean Microtiter Plates

    SBC: IONFIELD HOLDINGS LLC            Topic: NIDA

    i) The Phase 1 objectives are to develop and validate prototype components that may be readily integrated to create an instrument designed to meet the specifications defined by the NCATS Contract RFP. ii) B1-Microtiter plates commonly used for high throughput screening include 96 well (8x12), 384 well (16x24) or 1536 well (32x48) plates. The plates generally share common overall external dimens ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. FY-2013 Contract HHSN271201300010C, Topic 004. A High Throughput Assay for Neur

    SBC: VALA SCIENCES, INC.            Topic: NIDA

    The technical objectives from the original solicitation are presented below, along with a brief discussion relevant to the Neural Crest Cell Migration assay. 1) Develop a working assay in a 384 microwell format (the Phase II objective will be to adapt the assay to the 1536 well format). Cells will be cultured to confluence in a 384 well dish; the cell monolayer will then be scratched to crea ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. FY 2013 Contract HHSN271201300011C SBIR-I, Topic 004, RASL-Seq HTS Tox Profiler

    SBC: Biospyder Technologies, Inc.            Topic: NIDA

    The Contractor shall develop and implement a highly multiplexed targeted sequencing assay designed to detect toxicity during compound screening. The RASL-Seq HTS assay will monitor gene expression across 184 target genes and 20 housekeepi ng genes, in a format amenable to high throughput screening (HTS) that is cost effective and easy to use. Phase I will characterize assay performance using a set ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government